NCT07135466
- Conditions
- B Cell Malignancies, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
- Locations
-
- Sheba Medical Center Ramat Gan, G, Israel
Clinical trial condition
B Cell Malignancies
Explore clinical trials studying B Cell Malignancies. Study availability and eligibility vary by location and protocol.
13 public trials
2 recruiting studies
B Cell Malignancies trial results
NCT06375161
- Conditions
- B Cell Malignancies
- Locations
-
- Shanghai Tongji Hospital Shanghai, Shanghai Municipality, China
Not yet recruiting
4SCAR19U T Cells Targeting B Cell Malignancies
NCT05995015
- Conditions
- B Cell Malignancies
- Locations
-
- Shenzhen Geno-Immune Medical Institute Shenzhen, Guangdong, China
Not yet recruiting
CD19/22 Bi-specific CAR-T Cell Therapy
NCT05432882
- Conditions
- B Cell Malignancies
- Locations
-
- Shenzhen Geno-immune Medical Institute Shenzhen, Guangdong, China
Not yet recruiting
CD19/70 Bi-specific CAR-T Cell Therapy
NCT05436496
- Conditions
- B Cell Malignancies
- Locations
-
- Shenzhen Geno-immune Medical Institute Shenzhen, Guangdong, China
Not yet recruiting
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
NCT07503353
- Conditions
- Acute Lymphobkastic Leukemia, B Cell Malignancies, Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
- Locations
-
- Sheba Medical Center Ramat Gan, Israel
Not yet recruiting
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms
NCT07499635
- Conditions
- B Cell Malignancies
- Locations
-
Not specified
Not yet recruiting
Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection
NCT07332663
- Conditions
- B Cell Malignancies
- Locations
-
Not specified
Not yet recruiting
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
NCT07166549
- Conditions
- B Cell Lymphoma, B Cell Malignancies, B-cell Leukemia, +25 more
- Locations
-
- University Hospital Basel, Division of Hematology or Medical Oncology Basel, Canton of Basel-City, Switzerland
Not yet recruiting
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
NCT06519344
- Conditions
- B Cell Malignancies
- Locations
-
Not specified